Lupin Limited - Product Pipeline Review - 2016

  • ID: 3821680
  • Company Profile
  • 44 pages
  • Global Markets Direct
1 of 4
Lupin Limited - Product Pipeline Review - 2016

Summary

‘Lupin Limited - Product Pipeline Review, 2016’, provides an overview of the Lupin Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Lupin Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Lupin Limited
- The report provides overview of Lupin Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Lupin Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Lupin Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Lupin Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lupin Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lupin Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Figures

Lupin Limited Snapshot

Lupin Limited Overview

Key Information

Key Facts

Lupin Limited - Research and Development Overview

Key Therapeutic Areas

Lupin Limited - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Lupin Limited - Pipeline Products Glance

Lupin Limited - Late Stage Pipeline Products

Phase III Products/Combination Treatment Modalities

Lupin Limited - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Lupin Limited - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Lupin Limited - Unknown Stage Pipeline Products

Unknown Products/Combination Treatment Modalities

Lupin Limited - Drug Profiles

Biosimilar for Oncology

Product Description

Mechanism of Action

R&D Progress

etanercept biosimilar

Product Description

Mechanism of Action

R&D Progress

LND-101001

Product Description

Mechanism of Action

R&D Progress

LNP-1892

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Colon and Lung Cancer

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism

Product Description

Mechanism of Action

R&D Progress

Biosimilar for Diabetes

Product Description

Mechanism of Action

R&D Progress

Biosimilar for Inflammation

Product Description

Mechanism of Action

R&D Progress

Biosimilar for Ophthalmology

Product Description

Mechanism of Action

R&D Progress

Biosimilar for Viral Infections

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Autoimmune Diseases

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Infectious Diseases

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Pain and Inflammation

Product Description

Mechanism of Action

R&D Progress

Biosimilar for Endocrinology

Product Description

Mechanism of Action

R&D Progress

Lupin Limited - Pipeline Analysis

Lupin Limited - Pipeline Products by Target

Lupin Limited - Pipeline Products by Route of Administration

Lupin Limited - Pipeline Products by Molecule Type

Lupin Limited - Pipeline Products by Mechanism of Action

Lupin Limited - Recent Pipeline Updates

Lupin Limited - Dormant Projects

Lupin Limited - Company Statement

Lupin Limited - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Lupin Limited, Key Information

Lupin Limited, Key Facts

Lupin Limited - Pipeline by Indication, 2016

Lupin Limited - Pipeline by Stage of Development, 2016

Lupin Limited - Monotherapy Products in Pipeline, 2016

Lupin Limited - Phase III, 2016

Lupin Limited - Phase II, 2016

Lupin Limited - Phase I, 2016

Lupin Limited - Preclinical, 2016

Lupin Limited - Discovery, 2016

Lupin Limited - Unknown, 2016

Lupin Limited - Pipeline by Target, 2016

Lupin Limited - Pipeline by Route of Administration, 2016

Lupin Limited - Pipeline by Molecule Type, 2016

Lupin Limited - Pipeline Products by Mechanism of Action, 2016

Lupin Limited - Recent Pipeline Updates, 2016

Lupin Limited - Dormant Developmental Projects,2016

Lupin Limited, Other Locations

Lupin Limited, Subsidiaries 40List of Figures

Lupin Limited - Pipeline by Top 10 Indication, 2016

Lupin Limited - Pipeline by Stage of Development, 2016

Lupin Limited - Monotherapy Products in Pipeline, 2016

Lupin Limited - Pipeline by Target, 2016

Lupin Limited - Pipeline by Route of Administration, 2016

Lupin Limited - Pipeline by Molecule Type, 2016

Lupin Limited - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll